A new study published in Alimentary Pharmacology & Therapeutics has revealed that lean individuals with metabolic dysfunction–associated steatotic liver disease (MASLD) face a comparable risk of developing significant liver fibrosis as overweight or obese patients. The research highlights that genetic factors, rather than body weight alone, may play a critical role in determining fibrosis risk in MASLD. These findings challenge the traditional assumption that fibrosis severity is primarily linked to obesity and metabolic load, suggesting that lean MASLD should not be underestimated in clinical assessment. The investigators conducted a detailed analysis of patients with MASLD across varying body mass index (BMI) categories, assessing fibrosis prevalence in relation to genetic risk scores

See Full Page